A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: CAB LA + RPV LA
DRUG: Oral ART

Sponsor

ViiV Healthcare